Eptinezumab Approval Status
FDA Approved: No
Generic name: eptinezumab
Company: Alder BioPharmaceuticals, Inc.
Treatment for: Migraine Prevention
Eptinezumab is an investigational monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) in development for migraine prevention.
Development Status and FDA Approval Process for eptinezumab
|Jun 27, 2017||Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.